Ayala Pharmaceuticals, Inc. (AYLA)

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) and Advaxis, Inc. is fair to Ayala shareholders. Upon completion of the merger, Ayala stockholders would own approximately 62.5% of the combined company’s outstanding common stock. Halper Sadeh encourages Ayala shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ayala and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Ayala shareholders; and (2) disclose all material information necessary for Ayala shareholders to adequately assess and value the merger consideration. On behalf of Ayala shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages Ayala shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Ayala Pharmaceuticals, Inc. (AYLA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study

The beaten-down stock market has created an opportunity for contrarian investors in short-squeeze stocks. Essentially, bearish traders must borrow the underlying securities which they are pessimistic about.

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 20.59% and 95.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Hot low float penny stocks to watch. The post Penny Stocks To Buy Now?

REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will participate in a “Fireside Chat” presentation at the Jefferies Healthcare Conference, to take place June 8-10, 2022, in New York, NY. The company will also be available for one-on-one meetings with institutional investors at the conference.

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 7.04% and 57.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the 32nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022. The company will also participate in one-on-one investor meetings at the conference.

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations.  The data was presented at the 2021 ESMO Virtual Congress (ESMO21).